Can you make it to the top of our NASH leaderboard? Join us for a satellite symposium on the nonalcoholic steatohepatitis (NASH) epidemic and put your skills to the test! Using a novel gamified approach, you’ll compete with your peers while learning about the complex disease state and economic burden of NASH. Don’t miss this opportunity to hear from multiple experts in the field and find out how you measure up!
NASH: An Epidemic with Enormous Health and Economic Implications
Do you understand the economic burden of NASH and its potential impact on patients’ quality of life? Play along in this symposium and prove it!
Live
Meeting
1.50 available credits
Information
March 21, 2023
06:00 PM - 08:00 PM CDT
Henry B. González Convention Center
900 E Market St, San Antonio, TX 78205
Share
Share
Share
Share this program on:
Details
Presenters
Comments
Program Schedule*
Click Here to Download the Slide Deck
6:00 pm – 6:30 pm
Registration and Dinner
6:30 pm – 6:35 pm
Welcome and Introduction
Steven Flamm, MD6:35 pm – 6:45 pm
What Are the Main Risk Factors for NASH and Who Should Be Identifying Them?
Steven Flamm, MD6:45 pm – 6:55 pm
Panel Discussion: What Are the Health Consequences of NASH?
Moderator: Steven Flamm, MD6:55 pm – 7:05 pm
How Do You Mitigate Risk?
Mazen Noureddin, MD7:05 pm – 7:15 pm
Panel Discussion: What Are the Economic Consequences of NASH?
Moderator: Tiffany Kaiser, PharmD7:15 pm – 7:25 pm
How Is Fatty Liver Disease Treated and Managed: NAFLD vs NASH
Mazen Noureddin, MD7:25 pm – 7:35 pm
Emerging Pharmacotherapeutics for NASH
Mazen Noureddin, MD7:35 pm – 7:45 pm
Panel Discussion: How Will the New Pharmacotherapeutics Impact the Economic Consequences of NASH?
Moderator: Tiffany Kaiser, PharmD7:45 pm –8:00 pm
Post-Test, Q&A, and Closing Remarks
Steven Flamm, MD*Subject to change
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Moderator:
Steven Flamm, MD
Professor of Medicine and Surgery
Rush University Medical Center
Chicago, ILResearch: Madrigal Pharmaceuticals
Faculty:
Tiffany E. Kaiser, PharmD, MS, FCCP
Associate Research Professor of Medicine
Division of Digestive Diseases
University of Cincinnati
Cincinnati, OHConsulting Fees: Eurofins Scientific, Wolters Kluwer (UpToDate)
Other: American College of Clinical PharmacyMazen Noureddin, MD
Medical Director
Houston Research Institute
Houston, TXAdvisory Board: Altimmune, BI, BMS, 89BIO, EchoSens, Gilead, GSK, Merck, Novo Nordisk, OWL, Pfizer, Roche diagnostic and Siemens, Terns and Takeda
Principal Investigator for a Drug Study: Allergan, Akero, BMS, Gilead, Galectin, Genfit, Conatus, Corcept, Enanta, Madrigal, Novartis, Novo Nordisk, Shire, Terns, Viking and Zydus
Stockholder: Anaetos, Rivus Pharma, CIMA, ChronWell and Viking
Editorial Board: Gastroenterology
Associate Editor: Clinical Gastroenterology and Hepatology
Federal funding: NIH/NIDDKReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Libby Lurwick has nothing to disclose.
- John Maeglin has nothing to disclose.
- Kate Nagele has nothing to disclose.
- Jay Runyon has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Explain the benefit of early diagnosis and risk stratification for health outcomes in patients with nonalcoholic fatty liver disease (NAFLD)
- Summarize the health and economic impacts of nonalcoholic steatohepatitis (NASH)
- Differentiate between treatment of NAFLD and treatment of NASH
- Identify the FDA-defined efficacy endpoint of investigational treatments of NASH
Target Audience
This activity is designed to meet the educational needs of managed care pharmacists and other managed care professionals, specialty and primary care physicians, physician assistants, nurse practitioners, and nurses.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-22-072-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Details
Presenters
Comments
Overview
Can you make it to the top of our NASH leaderboard? Join us for a satellite symposium on the nonalcoholic steatohepatitis (NASH) epidemic and put your skills to the test! Using a novel gamified approach, you’ll compete with your peers while learning about the complex disease state and economic burden of NASH. Don’t miss this opportunity to hear from multiple experts in the field and find out how you measure up!
Program Schedule*
Click Here to Download the Slide Deck
6:00 pm – 6:30 pm
Registration and Dinner
6:30 pm – 6:35 pm
Welcome and Introduction
Steven Flamm, MD6:35 pm – 6:45 pm
What Are the Main Risk Factors for NASH and Who Should Be Identifying Them?
Steven Flamm, MD6:45 pm – 6:55 pm
Panel Discussion: What Are the Health Consequences of NASH?
Moderator: Steven Flamm, MD6:55 pm – 7:05 pm
How Do You Mitigate Risk?
Mazen Noureddin, MD7:05 pm – 7:15 pm
Panel Discussion: What Are the Economic Consequences of NASH?
Moderator: Tiffany Kaiser, PharmD7:15 pm – 7:25 pm
How Is Fatty Liver Disease Treated and Managed: NAFLD vs NASH
Mazen Noureddin, MD7:25 pm – 7:35 pm
Emerging Pharmacotherapeutics for NASH
Mazen Noureddin, MD7:35 pm – 7:45 pm
Panel Discussion: How Will the New Pharmacotherapeutics Impact the Economic Consequences of NASH?
Moderator: Tiffany Kaiser, PharmD7:45 pm –8:00 pm
Post-Test, Q&A, and Closing Remarks
Steven Flamm, MD*Subject to change
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Moderator:
Steven Flamm, MD
Professor of Medicine and Surgery
Rush University Medical Center
Chicago, ILResearch: Madrigal Pharmaceuticals
Faculty:
Tiffany E. Kaiser, PharmD, MS, FCCP
Associate Research Professor of Medicine
Division of Digestive Diseases
University of Cincinnati
Cincinnati, OHConsulting Fees: Eurofins Scientific, Wolters Kluwer (UpToDate)
Other: American College of Clinical PharmacyMazen Noureddin, MD
Medical Director
Houston Research Institute
Houston, TXAdvisory Board: Altimmune, BI, BMS, 89BIO, EchoSens, Gilead, GSK, Merck, Novo Nordisk, OWL, Pfizer, Roche diagnostic and Siemens, Terns and Takeda
Principal Investigator for a Drug Study: Allergan, Akero, BMS, Gilead, Galectin, Genfit, Conatus, Corcept, Enanta, Madrigal, Novartis, Novo Nordisk, Shire, Terns, Viking and Zydus
Stockholder: Anaetos, Rivus Pharma, CIMA, ChronWell and Viking
Editorial Board: Gastroenterology
Associate Editor: Clinical Gastroenterology and Hepatology
Federal funding: NIH/NIDDKReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Libby Lurwick has nothing to disclose.
- John Maeglin has nothing to disclose.
- Kate Nagele has nothing to disclose.
- Jay Runyon has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Explain the benefit of early diagnosis and risk stratification for health outcomes in patients with nonalcoholic fatty liver disease (NAFLD)
- Summarize the health and economic impacts of nonalcoholic steatohepatitis (NASH)
- Differentiate between treatment of NAFLD and treatment of NASH
- Identify the FDA-defined efficacy endpoint of investigational treatments of NASH
Target Audience
This activity is designed to meet the educational needs of managed care pharmacists and other managed care professionals, specialty and primary care physicians, physician assistants, nurse practitioners, and nurses.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-22-072-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Facebook Comments
Recommended
Harnessing the NAFLD/NASH Epidemic: Preparing for a New Treatment Paradigm
Harnessing the NAFLD/NASH Epidemic: Preparing for a New Treatment Paradigm
CME/CEHarnessing the NAFLD/NASH Epidemic: Preparing for a New Treatment Paradigm
0.25 credits0.25 creditsRevolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
CME/CERevolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
0.25 credits0.25 creditsLet’s Rewind: Recognizing NAFLD/NASH in the Primary Care Clinic
Let’s Rewind: Recognizing NAFLD/NASH in the Primary Care Clinic
CME/CELet’s Rewind: Recognizing NAFLD/NASH in the Primary Care Clinic
0.25 credits0.25 creditsTreat or Refer: Who Is Responsible for Managing Gout?
Treat or Refer: Who Is Responsible for Managing Gout?
MinuteCE®Treat or Refer: Who Is Responsible for Managing Gout?
1.00 program credit1.00 program credit
Facebook Comments